PriceTargets.com logo

Zenas BioPharma - ZBIO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $46.71
  • Forecasted Upside: 64.54%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$28.39 As of 10/30/2026 05:00 PM ET
▼ -0.37 (-1.29%)

This chart shows the closing price for ZBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zenas BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZBIO

Analyst Price Target is $46.71
▲ +64.54% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Zenas BioPharma in the last 3 months. The average price target is $46.71, with a high forecast of $55.00 and a low forecast of $32.00. The average price target represents a 64.54% upside from the last price of $28.39.

This chart shows the closing price for ZBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in Zenas BioPharma. This rating has held steady since May 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/10/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/8/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/6/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/4/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
5/5/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
8/3/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/2/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/1/2026

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/28/2026CitigroupReiterated RatingBuy ➝ Buy
10/23/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
10/20/2026Morgan StanleyInitiated CoverageEqual Weight$32.00
10/13/2026HC WainwrightReiterated RatingBuy ➝ Buy$44.00
10/6/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/30/2026CitigroupBoost TargetBuy ➝ Buy$41.00 ➝ $48.00
9/30/2026GuggenheimReiterated RatingBuy ➝ Buy$55.00
9/30/2026WedbushReiterated RatingOutperform ➝ Outperform$45.00
9/30/2026HC WainwrightReiterated RatingBuy ➝ Buy$44.00
8/14/2026Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$22.00 ➝ $32.00
8/14/2026GuggenheimReiterated RatingBuy ➝ Buy$55.00
8/14/2026WedbushReiterated RatingOutperform ➝ Outperform$45.00
7/9/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
6/24/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/3/2026CitigroupReiterated RatingBuy ➝ Buy
6/3/2026HC WainwrightReiterated RatingBuy ➝ Buy
5/15/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
5/15/2026HC WainwrightReiterated RatingBuy ➝ Buy$44.00
5/14/2026Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$21.00 ➝ $22.00
5/14/2026CitigroupReiterated RatingBuy ➝ Buy
3/27/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/17/2026Zacks ResearchDowngradeHold ➝ Strong Sell
3/17/2026CitigroupLower TargetBuy ➝ Buy$43.00 ➝ $41.00
3/17/2026HC WainwrightReiterated RatingBuy ➝ Buy$44.00
3/17/2026Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$19.00 ➝ $21.00
3/16/2026GuggenheimBoost TargetBuy ➝ Buy$45.00 ➝ $55.00
2/10/2026HC WainwrightReiterated RatingBuy ➝ Buy$44.00
1/6/2026Jefferies Financial GroupReiterated RatingBuy ➝ Buy$48.00
1/5/2026Morgan StanleyDowngradeOverweight ➝ Equal Weight$37.00 ➝ $19.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025WedbushReiterated RatingOutperform ➝ Outperform$45.00
12/16/2025HC WainwrightReiterated RatingBuy ➝ Buy
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/26/2025EvercoreInitiated CoverageOutperform$55.00
11/13/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$34.00 ➝ $37.00
10/30/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/28/2025CitigroupBoost TargetBuy ➝ Buy$27.00 ➝ $46.00
10/28/2025HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $44.00
10/27/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$31.00 ➝ $34.00
10/27/2025Jefferies Financial GroupReiterated RatingBuy ➝ Buy$52.00
10/27/2025WedbushReiterated RatingOutperform$40.00 ➝ $45.00
10/9/2025WedbushBoost TargetOutperform ➝ Outperform$35.00 ➝ $40.00
10/9/2025HC WainwrightReiterated RatingBuy ➝ Buy$30.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
5/16/2025HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/15/2025WedbushReiterated RatingOutperform$35.00
3/20/2025WedbushInitiated CoverageOutperform$35.00
3/12/2025GuggenheimReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
(Data available from 11/1/2021 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2026
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2026
  • 1 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2026

Current Sentiment

  • 1 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Zenas BioPharma logo
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $28.39
Low: $27.91
High: $29.11

50 Day Range

MA: $29.48
Low: $24.84
High: $33.77

52 Week Range

Now: $28.39
Low: $13.50
High: $44.60

Volume

358,069 shs

Average Volume

570,684 shs

Market Capitalization

$1.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Zenas BioPharma?

The following equities research analysts have issued stock ratings on Zenas BioPharma in the last twelve months: Citigroup Inc., Evercore Inc, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Wall Street Zen, Wedbush, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for ZBIO.

What is the current price target for Zenas BioPharma?

0 Wall Street analysts have set twelve-month price targets for Zenas BioPharma in the last year. Their average twelve-month price target is $46.71, suggesting a possible upside of 64.5%. Evercore Inc has the highest price target set, predicting ZBIO will reach $55.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $32.00 for Zenas BioPharma in the next year.
View the latest price targets for ZBIO.

What is the current consensus analyst rating for Zenas BioPharma?

Zenas BioPharma currently has 1 sell rating, 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ZBIO.

What other companies compete with Zenas BioPharma?

Other companies that are similar to Zenas BioPharma include AbbVie, AbCellera Biologics, Abeona Therapeutics, AC Immune and ACADIA Pharmaceuticals. Learn More about companies similar to Zenas BioPharma.

How do I contact Zenas BioPharma's investor relations team?

Zenas BioPharma's physical mailing address is 852 WINTER STREET, SUITE 250, WALTHAM, MA, 02451. The company's listed phone number is (857) 271-2954 and its investor relations email address is [email protected]. The official website for Zenas BioPharma is zenasbio.com. Learn More about contacing Zenas BioPharma investor relations.